Journal Article

Can Routine Clinical Markers Be Used Longitudinally to Monitor Antiretroviral Therapy Success in Resource-Limited Settings?

Shashwatee Bagchi, Mirjam C. Kempf, Andrew O. Westfall, Anastasiya Maherya, James Willig and Michael S. Saag

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 44, issue 1, pages 135-138
Published in print January 2007 | ISSN: 1058-4838
Published online January 2007 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/510072
Can Routine Clinical Markers Be Used Longitudinally to Monitor Antiretroviral Therapy Success in Resource-Limited Settings?

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Although routine clinical markers are used routinely to determine the stage of human immunodeficiency virus (HIV) disease, their use in monitoring response to antiretroviral therapy is poorly defined. Selected clinical markers were evaluated for their ability to predict first-line antiretroviral therapy success. No clinically meaningful variables were identified that predicted virologic or immunological success, implying that the CD4+ cell count and HIV type 1 RNA level data are required for optimal management of antiretroviral therapy.

Journal Article.  2207 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.